NYSE (USA) TSX (CANADA)

Directory of Stock Market Company

This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

AEZS - Aeterna Zentaris Inc

AEterna Zentaris Inc., incorporated on September 12, 1990, is a drug development company specialized in oncology and endocrine therapy. The Company’s product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The priorities in oncology are its Phase III program with perifosine in multiple myeloma and its Phase II pro","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

# AEZShart

Aeterna Zentaris Inc News


M&A Activity and a Growing Rate of FDA Approvals Contributing Factors to ...
EIN News (press release) - May 18, 2012
NEW YORK, NY -- (Marketwire) -- 05/18/12 -- The Biotechnology Industry has shown investors some impressive gains this year. The SPDR S&P Biotech ETF (XBI) is up nearly 25 percent year-to-date.

M&A Activity and a Growing Rate of FDA Approvals Contributing Factors to ...
MarketWatch (press release) - May 18, 2012
NEW YORK, NY, May 18, 2012 (MARKETWIRE via COMTEX) -- The Biotechnology Industry has shown investors some impressive gains this year.

Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price
Sacramento Bee - May 17, 2012
By AETERNA ZENTARIS INC. QUEBEC CITY, May 16, 2012 -- /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that it has received a notice from The NASDAQ Stock Market indicating that the Company's minimum bid ...

Aeterna Zentaris (AEZS) Gets Minimum Bid Notification from Nasdaq
StreetInsider.com (subscription) - May 16, 2012
Aeterna Zentaris Inc. (Nasdaq: AEZS) has received a notice from The NASDAQ Stock Market indicating that the Company's minimum bid price has fallen below $1.00 for 30 consecutive business days, and, therefore, was not in compliance with NASDAQ ...

The Case For Keryx Biopharmaceuticals' Analyst Upgrade May Be Justified
Seeking Alpha - May 16, 2012
An analyst upgrade last week and renewed investor interest in Keryx Biopharmaceuticals (KERX) had shares heavily on the move over the past week, a move initially sparked, in part, by positive Phase III data for Zerenex in Japan.

5 Biotech Stocks At Rock Bottom Price With Takeover Possibility
Seeking Alpha - May 11, 2012
So far, 2012 has been the best year for the Biotechnology and Drugs industry. So many stocks have surged in the last four months based on clinical trial results, US Food and Drug Administration (FDA) approval, FDA Advisory Committee's recommendation, ...

Aeterna Zentaris loss widens on higher finance costs
Reuters Canada - May 9, 2012
(Reuters) - Canadian drugmaker Aeterna Zentaris Inc AEZ.TO (AEZS.O: Quote) posted a wider first-quarter loss as finance costs soared.

Aeterna Zentaris Reports First Quarter 2012 Financial and Operating Results
MarketWatch (press release) - May 9, 2012
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TOR:CA:AEZ) (the"Company"), today reported financial and operating results as at and for the first quarter ended March31, 2012.
Biotech Hot Potato - DailyFinance

Aeterna Zentaris Reports First Quarter 2012 Financial and Operating Results
PR Newswire (press release) - May 9, 2012
QUEBEC CITY, May 9, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today reported financial and operating results as at and for the first quarter ended March 31, 2012.

Novavax (NASDAQ:NVAX) Shares Surges on Healthy Results- NVAX, KERX, DNDN, ARNA ...
eStocksDaily - May 7, 2012
Novavax Inc (NASDAQ:NVAX) shares climbed 2.22 percent to $1.38 following the firm posted Q1 results. Net loss was $7.3 million or $0.06 a share evaluated with net loss of $7.5 million or $0.07 a share in the Q1 of 2011.

NYSE Media Coverage Selection of the best articles found in your favorit medias

Next Company >>